Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma

Milada Stuchlová Horynová; Milan Raška; Henrik Clausen; Jan Novak

doi:10.1007/s00018-012-1082-6

Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma

Milada Stuchlová Horynová, Milan Raška, Henrik Clausen, Jan Novak

Glycomics Program

43 Citations (Scopus)

Abstract

Glycosylation abnormalities have been observed in autoimmune diseases and cancer. Here, we compare mechanisms of aberrant O-glycosylation, i.e., formation of Tn and sialyl-Tn structures, on MUC1 in breast cancer, and on IgA1 in an autoimmune disease, IgA nephropathy. The pathways of aberrant O-glycosylation, although different for MUC1 and IgA1, include dysregulation in glycosyltransferase expression, stability, and/or intracellular localization. Moreover, these aberrant glycoproteins are recognized by antibodies, although with different consequences. In breast cancer, elevated levels of antibodies recognizing aberrant MUC1 are associated with better outcome, whereas in IgA nephropathy, the antibodies recognizing aberrant IgA1 are part of the pathogenetic process.

Original language	English
Journal	Cellular and Molecular Life Sciences
Volume	70
Issue number	5
Pages (from-to)	829-839
Number of pages	11
ISSN	1420-682X
DOIs	https://doi.org/10.1007/s00018-012-1082-6
Publication status	Published - Mar 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00018-012-1082-6

Cite this

@article{6501e50327ff488da78f76ddf5781a9c,

title = "Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma",

abstract = "Glycosylation abnormalities have been observed in autoimmune diseases and cancer. Here, we compare mechanisms of aberrant O-glycosylation, i.e., formation of Tn and sialyl-Tn structures, on MUC1 in breast cancer, and on IgA1 in an autoimmune disease, IgA nephropathy. The pathways of aberrant O-glycosylation, although different for MUC1 and IgA1, include dysregulation in glycosyltransferase expression, stability, and/or intracellular localization. Moreover, these aberrant glycoproteins are recognized by antibodies, although with different consequences. In breast cancer, elevated levels of antibodies recognizing aberrant MUC1 are associated with better outcome, whereas in IgA nephropathy, the antibodies recognizing aberrant IgA1 are part of the pathogenetic process.",

author = "{Stuchlov{\'a} Horynov{\'a}}, Milada and Milan Ra{\v s}ka and Henrik Clausen and Jan Novak",

year = "2013",

month = mar,

doi = "10.1007/s00018-012-1082-6",

language = "English",

volume = "70",

pages = "829--839",

journal = "EXS",

issn = "1023-294X",

publisher = "Springer Basel AG",

number = "5",

}

TY - JOUR

T1 - Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma

AU - Stuchlová Horynová, Milada

AU - Raška, Milan

AU - Clausen, Henrik

AU - Novak, Jan

PY - 2013/3

Y1 - 2013/3

N2 - Glycosylation abnormalities have been observed in autoimmune diseases and cancer. Here, we compare mechanisms of aberrant O-glycosylation, i.e., formation of Tn and sialyl-Tn structures, on MUC1 in breast cancer, and on IgA1 in an autoimmune disease, IgA nephropathy. The pathways of aberrant O-glycosylation, although different for MUC1 and IgA1, include dysregulation in glycosyltransferase expression, stability, and/or intracellular localization. Moreover, these aberrant glycoproteins are recognized by antibodies, although with different consequences. In breast cancer, elevated levels of antibodies recognizing aberrant MUC1 are associated with better outcome, whereas in IgA nephropathy, the antibodies recognizing aberrant IgA1 are part of the pathogenetic process.

AB - Glycosylation abnormalities have been observed in autoimmune diseases and cancer. Here, we compare mechanisms of aberrant O-glycosylation, i.e., formation of Tn and sialyl-Tn structures, on MUC1 in breast cancer, and on IgA1 in an autoimmune disease, IgA nephropathy. The pathways of aberrant O-glycosylation, although different for MUC1 and IgA1, include dysregulation in glycosyltransferase expression, stability, and/or intracellular localization. Moreover, these aberrant glycoproteins are recognized by antibodies, although with different consequences. In breast cancer, elevated levels of antibodies recognizing aberrant MUC1 are associated with better outcome, whereas in IgA nephropathy, the antibodies recognizing aberrant IgA1 are part of the pathogenetic process.

U2 - 10.1007/s00018-012-1082-6

DO - 10.1007/s00018-012-1082-6

M3 - Journal article

C2 - 22864623

SN - 1023-294X

VL - 70

SP - 829

EP - 839

JO - EXS

JF - EXS

IS - 5

ER -

Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this